What is Poteligeo used to treat?

Intravenous Poteligeo (mogamulizumab-kpkc) is used for the treatment of adults with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Although these two conditions are rare, mycosis fungoides and Sézary syndrome are the most common subtypes of cutaneous T-cell lymphoma (CTCL), types of non-Hodgkin's lymphoma that first occur on the skin. Symptoms of CTCL may include a rash, tumors, swollen lymph nodes, skin thickening or lesions, and pruritus (itching).

How effective is Poteligeo and what are the side effects?

In a clinical trial of 332 patients, progression-free survival (time alive without cancer growth) was longer with Poteligeo at a median of 7.6 months compared to patients taking vorinostat (Zolinza) at a median of 3.1 months. Common side effects with Poteligeo included rash, infusion reactions, fatigue, diarrhea, musculoskeletal pain and upper respiratory tract infection.

See also:

Related medical questions

• Prednisone: What are 12 Things You Should Know?
• How and where is Adcetris administered?
• Is Adcetris a chemotherapy drug?

Drug information

• Mogamulizumab
• Poteligeo

Related support groups

• Mogamulizumab (1 questions, 3 members)
• Poteligeo (1 questions, 3 members)
• Mycosis Fungoides (4 questions, 5 members)

Medical Disclaimer